Header

UZH-Logo

Maintenance Infos

Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites


Ackermann, R; Semmler, A; Maurer, G D; Hattingen, E; Fornoff, F; Steinbach, J P; Linnebank, M (2010). Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. Journal of Neuro-Oncology, 97(3):425-427.

Abstract

Methotrexate (MTX)-associated myelopathy is a rare but serious subacute complication of MTX-based chemotherapy. We report the case of a woman with breast cancer and meningeal carcinomatosis who developed severe progressive myelopathy after four cycles of intrathecal MTX administration. We substituted high doses of the key metabolites of the methyl-transfer pathway: S-adenosylmethionine (SAM), 200 mg three times daily i.v.; folinate, 20 mg four times daily i.v.; cyanocobalamin, 100 mug once daily i.v.; and methionine, 5 g daily p.o. The patient's paraparesis improved rapidly thereafter, and magnetic resonance (MR) imaging showed resolution of the intramedullary lesions. Genetic analyses revealed homozygosity for the A allele of methylenetetrahydrofolate reductase (MTHFR) c.1298A>C (p.E429A), whereas other genetic variants of folate/methionine metabolism associated with MTX neurotoxicity were not present. Substitution with multiple folate metabolites may be a promising strategy for the treatment of MTX-induced neurotoxicity.

Abstract

Methotrexate (MTX)-associated myelopathy is a rare but serious subacute complication of MTX-based chemotherapy. We report the case of a woman with breast cancer and meningeal carcinomatosis who developed severe progressive myelopathy after four cycles of intrathecal MTX administration. We substituted high doses of the key metabolites of the methyl-transfer pathway: S-adenosylmethionine (SAM), 200 mg three times daily i.v.; folinate, 20 mg four times daily i.v.; cyanocobalamin, 100 mug once daily i.v.; and methionine, 5 g daily p.o. The patient's paraparesis improved rapidly thereafter, and magnetic resonance (MR) imaging showed resolution of the intramedullary lesions. Genetic analyses revealed homozygosity for the A allele of methylenetetrahydrofolate reductase (MTHFR) c.1298A>C (p.E429A), whereas other genetic variants of folate/methionine metabolism associated with MTX neurotoxicity were not present. Substitution with multiple folate metabolites may be a promising strategy for the treatment of MTX-induced neurotoxicity.

Statistics

Citations

17 citations in Web of Science®
18 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

442 downloads since deposited on 02 Nov 2009
69 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:May 2010
Deposited On:02 Nov 2009 11:40
Last Modified:05 Apr 2016 13:31
Publisher:Springer
ISSN:0167-594X
Additional Information:The original publication is available at www.springerlink.com
Publisher DOI:https://doi.org/10.1007/s11060-009-0028-9
PubMed ID:19821069

Download

Download PDF  'Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher